

**I/We Claim:**

1. An isolated antibody or antibody fragment which binds to human PD-1, comprising: light chain CDRs 1-3 SEQ ID NOs: 9, 10 and 11 respectively and heavy chain CDRs 1-3 SEQ ID NOs: 12, 13 and 14, respectively,

wherein said antibody or antibody fragment blocks binding of human PD-L1 and human PD-L2 to human PD-1.

2. The antibody or antibody fragment of claim 1, wherein said antibody or antibody fragment blocks binding of human PD-L1 and/or human PD-L2 to human PD-1 with an IC<sub>50</sub> of about 1 nM or lower.

3. An antibody or antibody fragment of any one of claims 1 to 2, comprising:

a. a heavy chain variable region comprising SEQ ID NO: 5; and

b. a light chain variable region comprising SEQ ID NO: 6.

4. The antibody of any one of claims 1 to 3, further comprising a heavy chain constant region comprising a  $\gamma$ 4 or  $\gamma$ 1 human heavy chain constant region.

5. The antibody or antibody fragment of any of the above claims, wherein the antibody or antibody fragment is:

a. a chimeric antibody or a fragment thereof;

b. a human antibody or a fragment thereof; or

c. a humanized antibody or a fragment thereof.

6. The antibody fragment of any of the above claims, wherein the antibody fragment is selected from the group consisting of Fab, Fab', Fab'-SH, Fv, scFv, F(ab')<sub>2</sub>, and a diabody.

7. The antibody or antibody fragment of any of the above claims, wherein the antibody or antibody fragment increases activation of T cells.
8. An isolated polynucleotide encoding the antibody or antibody fragment of any one of claims 1 to 7.
9. The isolated polynucleotide of claim 8, wherein the antibody comprises a heavy chain comprising SEQ ID NO: 5 and a light chain comprising SEQ ID NO: 6.
10. The isolated polynucleotide of claim 9, comprising SEQ ID NO: 1 and SEQ ID NO: 2.
11. An expression vector comprising the isolated polynucleotide of any one of claims 8 to 10.
12. A host cell comprising the expression vector of claim 11.
13. A method of producing an antibody or antibody fragment according to any one of claims 1 to 7 comprising:
  - a. culturing the host cell of claim 12 in culture medium under conditions wherein the nucleic acid sequence is expressed, thereby producing polypeptides comprising the light and heavy chain variable regions; and
  - b. recovering the polypeptides from the host cell or culture medium.
14. The method of claim 13, wherein the antibody comprises:
  - a. a heavy chain variable region comprising SEQ ID NO: 5; and
  - b. a light chain variable region comprising SEQ ID NO: 6.
15. A composition comprising the antibody or antibody fragment of any one of claims 1 to 7 in combination with a pharmaceutically acceptable carrier or diluent.
16. The composition of claim 15, wherein the antibody comprises:

a. a heavy chain variable region comprising SEQ ID NO: 5; and

b. a light chain variable region comprising SEQ ID NO: 6.

Dated **13 December 2017**

**MALATHI LAKSHMIKUMARAN**

**IN/PA- 1433**

**OF LAKSHMIKUMARAN & SRIDHARAN**

**AGENT FOR THE APPLICANT**

To

The Controller of Patents

The Patent Office, at **Chennai**

**I/We Claim:**

1. An isolated antibody or antibody fragment which binds to human PD-1, comprising: light chain CDRs 1-3 SEQ ID NOs: 9, 10 and 11 respectively and heavy chain CDRs 1-3 SEQ ID NOs: 12, 13 and 14, respectively,

wherein said antibody or antibody fragment blocks binding of human PD-L1 and human PD-L2 to human PD-1.

2. The antibody or antibody fragment of claim 1, wherein said antibody or antibody fragment blocks binding of human PD-L1 and/or human PD-L2 to human PD-1 with an IC<sub>50</sub> of about 1 nM or lower.

~~3. The antibody or antibody fragment of claim 1 or 2, comprising:~~

~~a. a heavy chain variable region comprising SEQ ID NO: 5 or a variant thereof, wherein said variant comprises one, two or three conservatively modified amino acids; and~~

~~b. a light chain variable region comprising SEQ ID NO: 6 or a variant thereof, wherein said variant comprises one, two or three conservatively modified amino acid substitutions.~~

~~43.~~ An antibody or antibody fragment of any one of claims 1 to ~~32~~, comprising:

a. a heavy chain variable region comprising SEQ ID NO: 5; and

b. a light chain variable region comprising SEQ ID NO: 6.

~~54.~~ The antibody of any one of claims 1 to ~~43~~, further comprising a heavy chain constant region comprising a  $\gamma$ 4 or  $\gamma$ 1 human heavy chain constant region.

~~65.~~ The antibody or antibody fragment of any of the above claims, wherein the antibody or antibody fragment is:

a. a chimeric antibody or a fragment thereof;

b. a human antibody or a fragment thereof; or

c. a humanized antibody or a fragment thereof.

~~76~~. The antibody fragment of any of the above claims, wherein the antibody fragment is selected from the group consisting of Fab, Fab', Fab'-SH, Fv, scFv, F(ab')<sub>2</sub>, and a diabody.

~~87~~. The antibody or antibody fragment of any of the above claims, wherein the antibody or antibody fragment increases activation of T cells.

~~98~~. An isolated polynucleotide encoding the antibody or antibody fragment of any one of claims 1 to ~~87~~.

~~109~~. The isolated polynucleotide of claim ~~98~~, wherein the antibody comprises a heavy chain comprising SEQ ID NO: 5 and a light chain comprising SEQ ID NO: 6.

~~140~~. The isolated polynucleotide of claim ~~109~~, comprising SEQ ID NO: 1 and SEQ ID NO: 2.

~~121~~. An expression vector comprising the isolated polynucleotide of any one of claims ~~98~~ to ~~140~~.

~~132~~. A host cell comprising the expression vector of claim ~~121~~.

~~143~~. A method of producing an antibody or antibody fragment according to any one of claims 1 to ~~87~~ comprising:

a. culturing the host cell of claim ~~132~~ in culture medium under conditions wherein the nucleic acid sequence is expressed, thereby producing polypeptides comprising the light and heavy chain variable regions; and

b. recovering the polypeptides from the host cell or culture medium.

~~154~~. The method of claim ~~143~~, wherein the antibody comprises:

a. a heavy chain variable region comprising SEQ ID NO: 5; and

b. a light chain variable region comprising SEQ ID NO: 6.

165. A composition comprising the antibody or antibody fragment of any one of claims 1 to 87 in combination with a pharmaceutically acceptable carrier or diluent.

176. The composition of claim 165, wherein the antibody comprises:

a. a heavy chain variable region comprising SEQ ID NO: 5; and

b. a light chain variable region comprising SEQ ID NO: 6.